FluoSphera Raises €1.23M To Advance Human-Relevant Preclinical Drug Testing Platform

The round was led by Soulmates Ventures and a Swiss business angel, with participation from IndieBio New York.

Developing new medicines is a long and expensive process, with many drug candidates failing in clinical trials. A key reason is the limited predictive power of current preclinical models.

Traditional two-dimensional cell cultures fail to capture interactions between organs, while animal models do not fully reflect human biology. As a result critical toxicities can be missed, leading to costly setbacks and delays in bringing effective treatments to patients.

Read Also - Spain’s Zepo Intelligence Secures €12.8 Million To Combat AI-Driven Human Cyber Risks

To overcome these limitations, FluoSphera has developed a multiplexed in vitro platform that predicts drug responses in a more human-relevant way. Its patented technology combines multiple human tissue models within a single experiment each tracked independently using proprietary fluorescent coding.

This approach allows researchers to study organ-to-organ interactions and evaluate both efficacy and potential side effects earlier in development, before advancing to animal or clinical testing.

Dr. Clélia Bourgoint, CEO and co-founder of FluoSphera, stated that the company is creating a new generation of preclinical tools designed to accelerate drug development, reduce costs, and enhance the quality of drug discovery.

By improving human relevance and reducing reliance on animal models, we help our partners bring safer, more effective treatments to patients faster.

FluoSphera’s platform helps drug developers reduce risk, accelerate timelines, and lower costs, while supporting regulatory frameworks promoting non-animal preclinical testing.

The new funding will expand business development, integrate the platform into workflows, enhance AI-based image analysis, and drive growth in the US, Europe and initial Asian markets.

About FluoSphera

FluoSphera S.A. is the only company offering a complete suite of high-throughput, systemic in vitro solutions for drug discovery, enabling more accurate prediction of drug efficacy and safety while reducing reliance on animal testing.